Loading…
Loading grant details…
| Funder | NATIONAL CANCER INSTITUTE |
|---|---|
| Recipient Organization | University of Illinois At Chicago |
| Country | United States |
| Start Date | Jul 15, 2024 |
| End Date | Jun 30, 2029 |
| Duration | 1,811 days |
| Number of Grantees | 1 |
| Roles | Principal Investigator |
| Data Source | NIH (US) |
| Grant ID | 10945084 |
ABSTRACT Title: WASp signaling in T-cell lymphomas Peripheral T-cell lymphomas (PTCL) are aggressive disorders, with less than 50% overall survival after 2-3-years of diagnosis. These dismal outcomes are in no small part secondary to the limited number of available biomarkers of disease progression and the limited knowledge of T-cell lymphoma biology. Emergent evidence
indicates that the actin cytoskeleton plays a pivotal role during T-cell lymphomas' development and growth; however, actin-related proteins' role as actionable targets in T-cell lymphomas still needs to be defined. Our preliminary findings demonstrate that the actin regulatory protein Wiskott-Aldrich syndrome protein (WASp) is
associated with decreased event-free survival and promotes T-cell lymphoma growth and survival. In this proposal, we will leverage a genetically engineered murine (GEM) model that develops spontaneous peripheral T-cell lymphomas (SNF5FL/CD4cre), and we will capitalize on an international consortium of more than 100 T-cell
lymphoma cases collected with accompanying annotated clinical outcomes, to test the role of WASp during the assembly of actin-dependent signaling complexes upstream of oncogenic transcriptional signaling, and define the role of the tumor microenvironment driving WASp-dependent oncogenic signaling.
University of Illinois At Chicago
Complete our application form to express your interest and we'll guide you through the process.
Apply for This Grant